Oleclumab

ESMO Congress 2024 showcased PIONeeR trial addressing PD-1/PD-L1 resistance in NSCLC, Rome trial's genomic-guided therapy improving outcomes in metastatic solid tumors, and Prov-GigaPath AI model for cancer mutation prediction and tumor microenvironment analysis.

2024 NSCLC highlights: osimertinib sets new standard for EGFR-mutant, unresectable stage III disease; lorlatinib offers unprecedented PFS in ALK-positive tumors; perioperative nivolumab improves EFS over neoadjuvant-only; novel agents enhance neoadjuvant durvalumab efficacy.

Durvalumab, with or without oleclumab, added to neoadjuvant chemotherapy and SBRT doubled pathologic complete response rates in high-risk HR-positive breast cancer patients, particularly in PD-L1–negative and node-positive subgroups, according to the Neo-CheckRay trial presented at ESMO Congress 2024.

Research at WCLC 2024 highlights potential treatments for NSCLC and ES-SCLC, including ivonescimab, aumolertinib, sacituzumab govitecan, N-803, durvalumab-based combinations, amivantamab plus lazertinib, ifinatamab deruxtecan, and sacituzumab govitecan. Trials show improved PFS, OS, and ORR with these treatments.

Durvalumab combined with datopotamab deruxtecan showed highest pathologic complete response rates in NeoCOAST-2 trial for resectable NSCLC, with 34.1% in arm 4, and a favorable safety profile.

DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.

Adding novel agents to perioperative durvalumab for NSCLC led to higher pCR and mPR rates compared to historical rates with durvalumab and chemotherapy. The highest response rates occurred with the addition of Dato-DXd (pCR 34.1%, mPR 65.9%). All combinations demonstrated manageable safety profiles and surgical rates comparable to approved regimens.

Innate Pharma announced AstraZeneca's interim NeoCOAST-2 Phase 2 study results at the 2024 World Conference on Lung Cancer, showing promising efficacy and safety profiles for monalizumab in early-stage NSCLC.

AstraZeneca presented interim results from the NeoCOAST-2 Phase 2 study at the 2024 World Conference on Lung Cancer, showing promising outcomes for early-stage non-small cell lung cancer patients across treatment arms. Monalizumab, in combination with durvalumab and platinum-based chemotherapy, demonstrated higher pathological complete response and major pathological response rates compared to the approved regimen, with a manageable safety profile.

The NeoCOAST-2 study showed durvalumab combined with Dato-DXd achieved the highest pathological complete response rates among tested regimens for resectable NSCLC, with Arm 4 yielding a 34.1% pCR rate and a favorable safety profile.